Text size :

Drugs: Prix Galien Italy to Italfarmaco for therapy in rare disease (3)

ADNKRONOS

November 4, 2026

(Adnkronos Health) – “The results of the first preclinical studies, on mouse models with Duchenne muscular dystrophy, were significant – explains Paolo Bettica, Chief Medical Officer, Drug Development Italfarmaco –. From here, the clinical development of the molecule began. In collaboration with patient associations and Italian clinicians, we designed a phase 2 study that allowed us to evaluate the effect of givinostat directly in the muscle, thanks to muscle biopsies performed after one year of treatment. This phase 2 study was conducted entirely in Italy. The observed results were very positive because they replicated what was observed in the murine model. We then promoted an international phase 3 registration study, Epidys, which demonstrated the benefit of givinostat both in functional terms and in the muscle, using nuclear magnetic resonance. The experience of patients with Duchenne muscular dystrophy and clinicians was crucial in identifying the relevant endpoints of the trials. Histone deacetylase inhibition has been studied in various diseases, but givinostat is the first drug of its class developed for Duchenne muscular dystrophy.”

“The recognition received – concludes Francesco Di Marco – rewards the scientific value of the molecule and its contribution to the Duchenne community, which offered fundamental support in carrying out clinical studies. The Prix Galien represents a moment of particular relevance in Italfarmaco’s journey, which has been able to combine solid scientific and entrepreneurial roots with a constant vocation for innovation. The recognition is not an arrival point, but a significant stage in a journey that continues. It reinforces Italfarmaco’s mission to transform scientific research into concrete value for patients and confirms our commitment that goes beyond the development of a therapy, embracing the broader goal of offering new perspectives to patients living with the disease and their families.”

Jiji Press

Related

Page TOP